Multimodal biomarkers in chikungunya arthritis: clinical phenotyping and a research agenda for personalized therapy

Background Chikungunya arthritis comprises overlapping pain-dominant, periarticular, inflammatory, and rheumatoid arthritis (RA)-like clinical phenotypes. Symptom duration alone does not capture this heterogeneity. Scope This narrative review evaluates virological assays, antiviral and autoimmune serology, inflammatory mediators, imaging, and clinical outcomes. Human observations are distinguished from animal and cell-based mechanisms. Findings Most biomarker evidence is exploratory. Associations with concurrent symptoms must be distinguished from prediction of later disease and from prediction of differential treatment benefit. Small samples, heterogeneous assays and sampling times, treatment exposure, and limited external validation restrict interpretation. Neither persistent antiviral antibodies nor an isolated cytokine elevation identifies a validated treatment-responsive subgroup. Tissue viral RNA or antigen does not establish productive infection or a causal explanation for persistent symptoms. Clinical phenotypes are observable states; proposed mechanistic endotypes remain unvalidated. Implications Current assessment should integrate disease phase, objective inflammation, functional burden, comorbidity, and alternative diagnoses. Evidence for methotrexate is limited by combination regimens, uncontrolled observations, and small comparative trials. Antivirals, neutralizing antibodies, and pathway-targeted immunomodulators remain investigational for CHIKV arthritis. Personalized treatment is a research agenda requiring longitudinal cohorts and prospective biomarker-by-treatment interaction trials, rather than a currently available biomarker-directed strategy.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-16
DOI
https://doi.org/10.3389/fimmu.2026.1959425
Primary Topic
Mosquito-borne diseases and control
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Multimodal biomarkers in chikungunya arthritis: clinical phenotyping and a research agenda for personalized therapy

Jiabao Xu, Xiaoling Chen, Yu Sheng, Siqi Zhang et al.
2 links
Frontiers in Immunology
Mosquito-borne diseases and control
article

Multimodal biomarkers in chikungunya arthritis: clinical phenotyping and a research agenda for personalized therapy

Jiabao Xu, Xiaoling Chen, Yu Sheng, Siqi Zhang, Shixian Chen, Junqing Zhu, Jiani Liu, Qingqing Zhang, Wenxia Lin, Ruifeng Lin, Hanbin Liu, Yangtao Liu, Xiaodong Wang, Hongjie Zhang, Qingyun Li, Meng Li, Juan Li
article en

Abstract

Background Chikungunya arthritis comprises overlapping pain-dominant, periarticular, inflammatory, and rheumatoid arthritis (RA)-like clinical phenotypes. Symptom duration alone does not capture this heterogeneity. Scope This narrative review evaluates virological assays, antiviral and autoimmune serology, inflammatory mediators, imaging, and clinical outcomes. Human observations are distinguished from animal and cell-based mechanisms. Findings Most biomarker evidence is exploratory. Associations with concurrent symptoms must be distinguished from prediction of later disease and from prediction of differential treatment benefit. Small samples, heterogeneous assays and sampling times, treatment exposure, and limited external validation restrict interpretation. Neither persistent antiviral antibodies nor an isolated cytokine elevation identifies a validated treatment-responsive subgroup. Tissue viral RNA or antigen does not establish productive infection or a causal explanation for persistent symptoms. Clinical phenotypes are observable states; proposed mechanistic endotypes remain unvalidated. Implications Current assessment should integrate disease phase, objective inflammation, functional burden, comorbidity, and alternative diagnoses. Evidence for methotrexate is limited by combination regimens, uncontrolled observations, and small comparative trials. Antivirals, neutralizing antibodies, and pathway-targeted immunomodulators remain investigational for CHIKV arthritis. Personalized treatment is a research agenda requiring longitudinal cohorts and prospective biomarker-by-treatment interaction trials, rather than a currently available biomarker-directed strategy.

Frontiers in ImmunologyVol. 17
Nanfang Hospital (CN), Southern Medical University (CN)
National Natural Science Foundation of China, China Postdoctoral Science Foundation
Good health and well-being
Mosquito-borne diseases and control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon